GlucoTrack Reports $4.3 Million Net Loss in Q1 2026, Focuses on Product Development

GlucoTrack, Inc. reported a net loss of $4.3 million for the first quarter of 2026, a significant improvement from the $6.8 million loss recorded in the same period of 2025. The company's total operating expenses increased to $4.2 million, up from $3.5 million year-over-year, primarily driven by higher research and development costs, which rose to $2.1 million from $1.9 million. General and administrative expenses also saw an increase, totaling $2.1 million compared to $1.6 million in the prior year. The reduction in net loss was attributed to a decrease in other expenses, particularly a notable reduction in the change in fair value of derivative liabilities.

In terms of liquidity, GlucoTrack's cash and cash equivalents decreased to $3.9 million as of March 31, 2026, down from $7.4 million at the end of 2025. The company utilized $4.0 million in cash for operating activities during the quarter, while it raised $591,000 through the sale of common stock under an equity line of credit (ELOC). The company has an accumulated deficit of $156.2 million and has indicated substantial doubt about its ability to continue as a going concern without additional financing.

Strategically, GlucoTrack is focused on the development of its implantable continuous blood glucose monitor (CBGM) technology, having withdrawn its previous product, the Glucotrack, from commercialization. The company has made progress in its clinical studies, including a first-in-human study completed in 2025, which demonstrated positive safety and performance results. Additionally, GlucoTrack submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study of its CBGM technology, marking a significant milestone in its product development efforts.

Operationally, the company has seen changes in its organizational structure, including the resignation of Chief Financial Officer Peter C. Wulff on March 31, 2026. The company has also engaged a clinical research organization to assist with its upcoming clinical trials. As of March 31, 2026, GlucoTrack had 2.5 million shares outstanding, a significant increase from 910,688 shares at the end of 2025, reflecting its efforts to raise capital through equity financing.

Looking ahead, GlucoTrack plans to continue its focus on product development and clinical trials while seeking additional financing to support its operations. The company has expressed intentions to explore various funding avenues, including equity and debt financing, to ensure it can meet its operational needs and advance its product offerings. However, the company cautions that there can be no assurance of successful capital raising efforts or that it will achieve its operational goals.